INT329292

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.54
First Reported 2010
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 3
Total Number 11
Disease Relevance 3.24
Pain Relevance 5.87

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleolus (Aff3) nucleus (Aff3)
Anatomy Link Frequency
Blood 4
nerves 1
Aff3 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 47 100.00 Very High Very High Very High
qutenza 423 99.52 Very High Very High Very High
Calcitonin gene-related peptide 36 85.92 High High
rheumatoid arthritis 56 84.40 Quite High
agonist 18 66.28 Quite High
Inflammatory response 2 61.56 Quite High
Pain 9 47.32 Quite Low
anesthesia 18 5.00 Very Low Very Low Very Low
tissue acidosis 9 5.00 Very Low Very Low Very Low
isoflurane 9 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Injury 198 99.44 Very High Very High Very High
Increased Venous Pressure Under Development 234 99.40 Very High Very High Very High
Acid Reflux 45 94.72 High High
Rheumatoid Arthritis 58 84.40 Quite High
INFLAMMATION 2 61.20 Quite High
Disease 14 60.48 Quite High
Necrosis 6 50.00 Quite Low
Cancer 6 50.00 Quite Low
Pressure And Volume Under Development 9 5.00 Very Low Very Low Very Low
Acidosis 9 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Laf was perfused during the basal and challenge periods (0–20 min) in the pH 1.0 + Laf and in the Cap-t (capsaicin pretreated) + pH 1.0 + Laf groups.
Gene_expression (perfused) of Laf associated with qutenza
1) Confidence 0.54 Published 2010 Journal Dig Dis Sci Section Body Doc Link PMC2958262 Disease Relevance 0.24 Pain Relevance 0.57
Our results demonstrated that luminal Laf perfusion increased blood flow in the absence of perfused luminal acid and that Laf enhanced acid-induced hyperemia, both mediated by CSAN, supporting our hypothesis that Laf sensitizes TRPV1 or submucosal afferent nerves.
Gene_expression (sensitizes) of Laf in nerves associated with increased venous pressure under development
2) Confidence 0.54 Published 2010 Journal Dig Dis Sci Section Body Doc Link PMC2958262 Disease Relevance 0.43 Pain Relevance 0.53
Data are expressed as mean ± SEM (n = 6). * p < 0.05 versus pH 7.0 Krebs group, † p < 0.05 versus veh-t + Laf group

Effect of Laf on Acid-Induced Changes in Esophageal pHint and Blood Flow

Gene_expression (expressed) of Laf in Blood
3) Confidence 0.49 Published 2010 Journal Dig Dis Sci Section Body Doc Link PMC2958262 Disease Relevance 0.16 Pain Relevance 0.82
A limitation of the current investigation is that no correction for multiple testing was applied and, if it was applied, the associations with change in DAS28 would not remain statistically significant (AFF3, pc=0.195; CD226, pc=0.624).
Neg (not) Gene_expression (significant) of AFF3
4) Confidence 0.48 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2930850 Disease Relevance 0.21 Pain Relevance 0.11
Two variants mapping to AFF3 and one to the CD226 locus demonstrated statistically significant evidence for association under an additive model (table 3) (AFF3: rs10865035, allele G coefficient ?
Gene_expression (coefficient) of AFF3
5) Confidence 0.48 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2930850 Disease Relevance 0.13 Pain Relevance 0.07
Since Laf ingestion, perhaps due to its indirect interaction with TRPV1, does not provoke a burning sensation, it might prove useful in the therapy of heartburn, acid-induced esophageal injury, and related disorders.
Gene_expression (ingestion) of Laf associated with acid reflux and injury
6) Confidence 0.47 Published 2010 Journal Dig Dis Sci Section Body Doc Link PMC2958262 Disease Relevance 0.45 Pain Relevance 0.51
Lafutidine (Laf), a histamine H2 receptor antagonist, has a mucosal protective effect in addition to its antisecretory properties via indirect stimulation or sensitization of CSAN [11–15].
Gene_expression (antagonist) of Laf associated with antagonist
7) Confidence 0.47 Published 2010 Journal Dig Dis Sci Section Body Doc Link PMC2958262 Disease Relevance 0.69 Pain Relevance 0.28
Laf was perfused during the basal and challenge periods (0–20 min) in the pH 1.0 + Laf and in the Cap-t (capsaicin pretreated) + pH 1.0 + Laf groups.
Gene_expression (perfused) of Laf associated with qutenza
8) Confidence 0.47 Published 2010 Journal Dig Dis Sci Section Body Doc Link PMC2958262 Disease Relevance 0.24 Pain Relevance 0.58
Data are expressed as mean ± SEM (n = 6). * p < 0.05 versus pH 7.0 Krebs group, † p < 0.05 versus pH 1.0 group, ‡ p < 0.05 versus pH 1.0 + Laf group

Effect of Laf on Acidified Pepsin-Induced Changes in Esophageal pHint and Blood Flow

Gene_expression (expressed) of Laf in Blood
9) Confidence 0.42 Published 2010 Journal Dig Dis Sci Section Body Doc Link PMC2958262 Disease Relevance 0.31 Pain Relevance 0.46
Data are expressed as mean ± SEM (n = 6). * p < 0.05 versus pH 7.0 Krebs group, † p < 0.05 versus pH 7.0 + Laf (0.1 mM) groupFig. 3Effect of capsaicin pretreatment (Cap-t) on Laf-induced changes in pHint and blood flow in rat esophagus.
Gene_expression (expressed) of Laf in blood associated with qutenza
10) Confidence 0.42 Published 2010 Journal Dig Dis Sci Section Body Doc Link PMC2958262 Disease Relevance 0.22 Pain Relevance 1.12
Data are expressed as mean ± SEM (n = 6). * p < 0.05 versus pH 7.0 Krebs group, † p < 0.05 versus veh-t + Laf group

Effect of Laf on Acid-Induced Changes in Esophageal pHint and Blood Flow

Gene_expression (expressed) of Laf in Blood
11) Confidence 0.42 Published 2010 Journal Dig Dis Sci Section Body Doc Link PMC2958262 Disease Relevance 0.16 Pain Relevance 0.82

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox